Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …
J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
The safety and side effects of monoclonal antibodies
TT Hansel, H Kropshofer, T Singer, JA Mitchell… - Nature reviews Drug …, 2010 - nature.com
Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …
transplant rejection, autoimmune and infectious diseases, as well as a range of new …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …
charged with reviewing, updating and categorizating indications for therapeutic apheresis …
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
CS Tan, IJ Koralnik - The Lancet Neurology, 2010 - thelancet.com
Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal brain disease
caused by reactivation of the polyomavirus JC. Knowledge of the characteristics of PML has …
caused by reactivation of the polyomavirus JC. Knowledge of the characteristics of PML has …
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
DB Clifford, A DeLuca, DM Simpson, G Arendt… - The Lancet …, 2010 - thelancet.com
Background Treatment of multiple sclerosis with natalizumab is complicated by rare
occurrence of progressive multifocal leukoencephalopathy (PML). Between July, 2006, and …
occurrence of progressive multifocal leukoencephalopathy (PML). Between July, 2006, and …
Immunological aspects of approved MS therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …
to disability in young adults. The outcome of the disease is unpredictable, and over time …
Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Apheresis Applications Committee of the American Society for …
ZM Szczepiorkowski, JL Winters… - Journal of clinical …, 2010 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Apheresis Applications Committee is
charged with a review and categorization of indications for therapeutic apheresis. Beginning …
charged with a review and categorization of indications for therapeutic apheresis. Beginning …